Generated by AI
GT Biopharma Inc. is a clinical-stage biopharmaceutical company focused on immuno-oncology therapies built around its proprietary TriKE platform. The company develops NK cell engager-based candidates designed to help natural killer cells recognize and attack cancer cells, supporting research in hematologic malignancies, solid tumors, and autoimmune conditions. Its current pipeline includes programs such as GTB-3650, GTB-5550, and GTB-7550, which reflect the company’s emphasis on targeted biologic therapies that work through immune cell engagement rather than traditional chemotherapy approaches. GT Biopharma’s work is centered on advancing novel cancer and immune-modulating treatments through product development, clinical research, and commercialization efforts in the biotechnology market.
Website315 Montgomery Street
San Francisco, CA, 94104
United States
The latest articles about GTBP.
This biotech stock recently released some pleasing findings from its recent cancer treatment study.
SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that it has been selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting taking place from November 4-8, 2026 in Phoenix, AZ. Oral Presentation Details
Summary of Oct 23's posts. Generated by AI.
Summary of Jan 15's posts. Generated by AI.
Detailed price information for GT Biopharma Inc (GTBP-Q) from The Globe and Mail including charting and trades.
No summary yet.
Summary of Oct 23's posts. Generated by AI.
Investors talking about GTBP also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.